home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410o.zip
/
M94A2867.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
3KB
|
44 lines
Document 2867
DOCN M94A2867
TI Didanosine (DDI) vs zidovudine (ZDV) in HIV patients.
DT 9412
AU Milini P; Casari S; Donisi A; Gregis G; Tomasoni D; Bergamasco A; Carosi
G; Inst. of Infectious and Tropical Dis., Univ. of Brescia, Italy.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):207 (abstract no. PB0256). Unique
Identifier : AIDSLINE ICA10/94369708
AB OBJECTIVE: To value efficacy and tollerability of DDI therapy versus ZDV
in patients with HIV infection. METHODS: A case-control, randomized,
open study. Patients (pts): ARC subjects (CDC '87) with CD4+ cell count
< 500, naive for antiretroviral therapy, without haematological,
hepatic, renal and pancreatic abnormalities. Drug dosage and schedule:
DDI mg 500-750/day or ZDV mg 600-800/day in according to body weight.
End points: Efficacy: progression to AIDS, death and trend of surrogate
markers (CD4+, p24Ag, beta 2-microglobulin). Tollerability: bone marrow
toxicity, liver, renal and pancreatic impairment. Statistical analysis:
Anova/Kruskall Wallis test, Chi-square, Fisher test (cut off = 0.05).
RESULTS: During the period 1990-1993, 21 pts were enrolled in the study
(M. 71.4%, F. 28.6%; IVDU 76.2%, heterosexual 23.8%) (DDI 42.9% and ZDV
57.1%). Both DDI and ZDV groups were homogeneous for sex, age, risk
factor, mean CD4+ (DDI = 252/cmm, ZDV = 200/cmm), p24 Ag and beta
2-microglobulin. In the two groups (DDI or ZDV) the median follow-up was
84 wks, the median treatment period was 81 wks. AIDS progression was
observed in 4 pts (19%) (3 pts in ZDV, 1 pt in DDI). Four pts died (2 in
ZDV and 2 in DDI). Significant differences were observed in the mean of
CD4+ at 72 wks (DDI = 532/cmm ZDV = 254/cmm; p = 0.02) and at 84 wks
(DDI = 450/cmm ZDV = 218/cmm; p = 0.03). No differences were observed in
p24 Ag titer and beta 2 microglobulin. We found a significant decrease
in Hgb and neutrophils for the ZDV group and an increase in uric acid
for the DDI group as signs of toxicity. CONCLUSIONS: Our data suggest a
higher efficacy of DDI therapy on CD4+ cell count trend and confirm its
better tollerability, in ARC patients.
DE Acquired Immunodeficiency Syndrome/PREVENTION & CONTROL AIDS-Related
Complex/*DRUG THERAPY Case-Control Studies Comparative Study
Didanosine/ADVERSE EFFECTS/*THERAPEUTIC USE Female Human Leukocyte
Count Male Treatment Outcome T4 Lymphocytes Zidovudine/ADVERSE
EFFECTS/*THERAPEUTIC USE CLINICAL TRIAL MEETING ABSTRACT RANDOMIZED
CONTROLLED TRIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).